Journal
HAEMATOLOGICA
Volume 92, Issue 7, Pages 994-995Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.10802
Keywords
acute promyelocytic leukemia; arsenic trioxide; FLT3 mutation; cytogenetics
Categories
Ask authors/readers for more resources
Ninety-eight newly diagnosed cases of PML-RAR alpha positive APL were treated with a regimen of single agent ATO. FLT3 activating mutations were seen in 33% and an additional cytogenetic finding was noted in 23.2%. FLT3 activating mutations were significantly associated with a bcr3 PML-RAR alpha isoform (p=0.012) and a delay in achieving a molecular remission (p=0.022). Neither FLT3 activating mutations nor secondary cytogenetic changes had an impact on clinical outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available